Showing results (81-90 of 108) with videos related to

Sort By:
Pageof 11
Lancet (London, England)|September 16, 2024
Tivozanib plus nivolumab versus tivozanib monotherapy in patients with renal cell carcinoma following an immune checkpoint inhibitor: results of the phase 3 TiNivo-2 StudyToni K Choueiri, Laurence Albiges, Philippe Barthélémy, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|July 6, 2023
Quality of life in the year after new diagnosis with advanced prostate cancer for Black and White individuals living in the USEmily M Rencsok, Natalie Slopen, Karen Autio, et al.
Communications Medicine|December 2, 2024
Blood-based tumor mutational burden impacts clinical outcomes of immune checkpoint inhibitor treated breast and prostate cancersReagan M Barnett, Albert Jang, Sree Lanka, et al.
Clinical Genitourinary Cancer|August 9, 2023
Outcomes of Consolidative Nephrectomy following Primary Immunotherapy in Advanced Renal Cell Carcinoma: A Multicenter AnalysisKevin Hakimi, Ava Saidian, Justine Panian, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 10, 2024
Final Overall Survival Analysis of S1500: A Randomized, Phase II Study Comparing Sunitinib With Cabozantinib, Crizotinib, and Savolitinib in Advanced Papillary Renal Cell CarcinomaPedro Barata, Catherine Tangen, Melissa Plets, et al.
Clinical Genitourinary Cancer|December 8, 2022
Treatment Rechallenge With Immune Checkpoint Inhibitors in Advanced Urothelial CarcinomaDimitrios Makrakis, Dimitra Rafailia Bakaloudi, Rafee Talukder, et al.
The Prostate|April 1, 2021
Comparison of germline mutations in African American and Caucasian men with metastatic prostate cancerElisa M Ledet, Earle F Burgess, Alexandra O Sokolova, et al.
JCO Precision Oncology|November 15, 2021
Differential Activity of PARP Inhibitors in <i>BRCA1</i>- Versus <i>BRCA2</i>-Altered Metastatic Castration-Resistant Prostate CancerFadi Taza, Albert E Holler, Wei Fu, et al.
Cancer Research Communications|July 30, 2024
High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II TrialChanning J Paller, Marianna L Zahurak, Adel Mandl, et al.
The Oncologist|June 27, 2023
Pathological Outcomes of Patients With Advanced Renal Cell Carcinoma Who Receive Nephrectomy Following ImmunotherapyJustine Panian, Ava Saidian, Kevin Hakimi, et al.
Pageof 11